Posted by Michael Wonder on 23 Aug 2021
Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz
23 August 2021 - Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis’ copycat drug Byooviz.
Byooviz (ranibizumab, also known as SB11) has been cleared for the same indications as Lucentis – including wet age-related macular degeneration and diabetic macular oedema – and will be sold in the EU by Biogen.
